A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder

Journal of Clinical Psychiatry

Volumn 70, Issue 4, 2009, Pages 550-561

  Liebowitz, Michael R ^a,e   Asnis, Gregory ^b   Mangano, Richard ^c,d   Tzanis, Evan ^c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

^d ADOLOR CORPORATION   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VENLAFAXINE;

ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; FEMALE; HUMAN; HYPERTENSION; IMPOTENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PANIC; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; SOMNOLENCE; SUSTAINED DRUG RELEASE; SWEATING; XEROSTOMIA;

AMBULATORY CARE; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; PANIC DISORDER; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 66349094280     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04238     Document Type: Article

References (49)

1. Kessler RC, Chiu WT, Jin R, et al. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006;63:415-424
2. Keller MB, Hanks DL. Course and outcome in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:551-570 (Pubitemid 23192597)
3. Grant BF, Hasin DS, Stinson FS, et al. The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006;67:363-374
4. Shear MK, Maser JD. Standardized assessment for panic disorder research: a conference report. Arch Gen Psychiatry 1994;51:346-354 (Pubitemid 24176812)
5. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998;155:36-42 (Pubitemid 28037546)
6. Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-379 (Pubitemid 26197752)
7. Sheehan DV, Burnham DB, Iyengar MK, et al. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry 2005;66(1):34-40
8. Londborg PD, Wolkow R, Smith WT, et al. Sertraline in the treatment of panic disorder: a multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998;173:54-60 (Pubitemid 28312204)
9. Pollack MH, Otto MW, Worthington JJ, et al. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 1998;55:1010-1016 (Pubitemid 28506843)
10. Rapaport MH, Pollack M, Wolkow R, et al. Is placebo response the same as drug response in panic disorder? Am J Psychiatry 2000;157:1014-1016
11. Michelson D, Lydiard RB, Pollack MH, et al, and the Fluoxetine Panic Disorder Study Group. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry 1998;155:1570-1577
12. Michelson D, Pollack M, Lydiard RB, et al, and the Fluoxetine Panic Disorder Study Group. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. Br J Psychiatry 1999;174:213-218
13. Tiller JW, Bouwer C, Behnke K, for the International Panic Disorder Study Group. Moclobemide and fluoxetine for panic disorder. Eur Arch Psychiatry Clin Neurosci 1999;249(suppl 1):7-10
14. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404 (Pubitemid 34499333)
15. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241 (Pubitemid 32183606)
16. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001;179:15-22 (Pubitemid 32613392)
17. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 2000;283(23):3082-3088 (Pubitemid 30399718)
18. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000;157:968-974 (Pubitemid 30412349)
19. Allgulander C, Mangano R, Zhang J, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004;19:387-396 (Pubitemid 39172803)
20. Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005;66(2):238-247 (Pubitemid 40314332)
21. Rickels K, Mangano R, Khan A. Double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 2004;24(5):488-496 (Pubitemid 39274203)
22. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005;62:190-198 (Pubitemid 40189136)
23. US Food and Drug Administration. Drug details for venlafaxine. Washington, DC: US Dept Health Human Services; 2007. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed July 8, 2008
24. Geracioti TD Jr. Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 1995;56(9):408-410
25. Papp LA, Sinha SS, Martinez JM, et al. Low-dose venlafaxine treatment in panic disorder. Psychopharmacol Bull 1998;34:207-209 (Pubitemid 28292710)
26. Pollack MH, Worthington JJ 3rd, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996;32:667-670
27. Pollack MH, Lepola U, Koponen H, et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2007;24:1-14 (Pubitemid 46278675)
28. Pollack M, Mangano R, Entsuah R, et al. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology 2007;194:233-242 (Pubitemid 47457944)
29. Bradwejn J, Ahokas A, Stein DJ, et al. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005;187:352-359 (Pubitemid 41442388)
30. Sheehan DV. The Anxiety Disease. New York, NY: Charles Scribner's Sons; 1983
31. Shear MK, Brown TA, Barlow DH, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry 1997;154:1571-1575 (Pubitemid 27471351)
32. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication ADM 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
33. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
34. Minister of Health. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Good Clinical Practice: Consolidated Guideline. Available at: http://www.ottawaheart. ca/UOHI/hreb/document/goodclin-e.pdf. Accessed October 27, 2008
35. Lipman RS. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull 1982;18:69-77 (Pubitemid 13223885)
36. Raskin A. Age-sex differences in response to antidepressant drugs. J Nerv Ment Dis 1974;159:120-130
37. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
38. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
39. Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Ther 1979;17:263-267 (Pubitemid 10232022)
40. Sheehan DV. Sheehan Disability Scale. In: Rush AJ, Pincus HA, First MB, et al, eds. Handbook of Psychiatric Measures. 1st ed. Washington, DC: American Psychiatric Association; 2000:113-115
41. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-326 (Pubitemid 23311543)
42. Venlafaxine ER [package insert]. Philadelphia, Pa: Wyeth Pharmaceuticals; 2008
43. Barlow DH, Gorman JM, Shear MK, et al. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000;283:2529-2536 (Pubitemid 30324195)
44. Kamijima K, Kuboki T, Kumano H, et al. A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. Int Clin Psychopharmacol 2005;20:265-273 (Pubitemid 41192147)
45. Bandelow B, Behnke K, Lenoir S, et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry 2004;65(3):405-413
46. Basoglu M, Marks IM, Swinson RP, et al. Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure. J Affect Disord 1994;30:123-132 (Pubitemid 124012412)
47. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998;59(suppl 8):47-54 (Pubitemid 28354619)
48. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-1099
49. Ferguson JM, Khan A, Mangano R, et al. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry 2007;68(1):58-68 (Pubitemid 46220125)